To hear about similar clinical trials, please enter your email below
Trial Title:
Palliative Care Consultation to Improve Communication for Patients Considering Surgery for a Pancreatic Neoplasm
NCT ID:
NCT06545344
Condition:
Pancreatic Neoplasm
Conditions: Official terms:
Neoplasms
Pancreatic Neoplasms
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Supportive Care
Masking:
None (Open Label)
Intervention:
Intervention type:
Other
Intervention name:
Best Practice
Description:
Receive usual care
Arm group label:
Arm I (Usual care)
Other name:
standard of care
Other name:
standard therapy
Intervention type:
Procedure
Intervention name:
Palliative Care Consultation
Description:
Attend a palliative care visit
Arm group label:
Arm II (Palliative care visit)
Intervention type:
Other
Intervention name:
Survey Administration
Description:
Ancillary studies
Arm group label:
Arm I (Usual care)
Arm group label:
Arm II (Palliative care visit)
Intervention type:
Other
Intervention name:
Tumor Board Review
Description:
Undergo evaluation by tumor board
Arm group label:
Arm I (Usual care)
Arm group label:
Arm II (Palliative care visit)
Other name:
multidisciplinary opinion
Summary:
This clinical trial evaluates a palliative care consultation for improving communication
between providers and patients considering surgery for a pancreatic neoplasm. Pancreatic
operations have known complications that can affect quality of life. Palliative care has
been shown to improve patient reported quality of life and functional outcomes. Receiving
a palliative care consultation may improve communication and decision making for patients
considering surgery for a pancreatic neoplasm.
Detailed description:
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive usual care and undergo evaluation by a tumor board within 14 days
of baseline.
ARM II: Patients attend a palliative care visit over 60 minutes to discuss their illness,
quality of life, fears and concerns and communication preferences within 7 days of
baseline. Patients also undergo evaluation by a tumor board within 14 days of baseline.
After completion of study intervention, patients are followed up 7 days after the tumor
board visit and 90 days after initiation of treatment.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Adults (18 years or older)
- Pancreatic neoplasm pathology
- Ability to read, write, and speak in English
- Has decisional capacity
- Expected to be seen and discussed at PCSC and seeing a surgeon as part of their
tumor board evaluation
Exclusion Criteria:
- Metastatic pancreatic neoplasm
- Currently incarcerated
- Currently is or previously has received palliative care, or are unwilling to forego
palliative care for the first 90 days post randomization
- Evidence of any behavior, condition, or circumstance (including, but not limited to:
blindness, deafness, serious behavior or mental health conditions, discontinuing
curative treatment, lack of access to technology, etc) that would interfere with
their ability to complete study procedures as noted within the chart
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Fred Hutch/University of Washington Cancer Consortium
Address:
City:
Seattle
Zip:
98109
Country:
United States
Contact:
Last name:
Elizabeth Loggers
Phone:
206-667-7442
Email:
eloggers@fredhutch.org
Investigator:
Last name:
Elizabeth Loggers
Email:
Principal Investigator
Start date:
December 1, 2024
Completion date:
January 1, 2025
Lead sponsor:
Agency:
Fred Hutchinson Cancer Center
Agency class:
Other
Source:
Fred Hutchinson Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06545344
